Patents Assigned to The United States of America, as represented by the Secretary, Department of Health and Human
-
Publication number: 20230355126Abstract: Multidimensional MRI-based methods permit identification and categorization of brain specimens to identify sub-voxel tissue components that are specific to traumatic axon injury or other lesions. Lower dimensional MR spectral data is acquired and processed to provide multidimensional MR data of higher dimensions. One or more spectral ranges are selected that define signatures for brain injury and evaluation of the multidimensional MR data in these ranges is used to locate voxels associated with brain injury. For example, partial one dimensional data sets such as T1, T2, and mean diffusion coefficient (MD) data sets can be combined to provide two dimensional data sets such as T1-T2, MD-T2, and MD-T1 data sets. Using the spectral signatures, a specimen image can be produced showing areas of lesser or greater injury.Type: ApplicationFiled: July 14, 2021Publication date: November 9, 2023Applicants: The Henry M. Jackson Foundation for the Advancement for the Advancement of Military Medicine, Inc., The United States of America, as represented by the Secretary, Department of Health and Human ServicInventors: Dan Haim Benjamini, Peter J. Basser, Diego Iacono
-
Patent number: 11806406Abstract: The present disclosure is directed to methods and compositions for the diagnosis and/or treatment of tumors, such as ocular tumors, using virus-like particles conjugated to photosensitive molecules.Type: GrantFiled: August 5, 2021Date of Patent: November 7, 2023Assignees: Aura Biosciences, Inc., The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Elisabet de los Pinos, John Todd Schiller, Rhonda C. Kines, John MacDougall
-
Patent number: 11806369Abstract: Methods are disclosed herein for treating glaucoma in a subject. In some embodiments, the methods increase retinal ganglion cell survival. The disclosed methods use exosomes and/or miRNA.Type: GrantFiled: June 7, 2021Date of Patent: November 7, 2023Assignee: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human ServicesInventors: Stanislav Ivanovich Tomarev, Benjamin Frank John Martin Mead
-
Publication number: 20230346797Abstract: Disclosed are inhibitors of the plasmodial surface anion channel (PSAC) inhibitors and the use thereof in treating or preventing malaria in an animal such as a human, comprising administering an effective amount of an inhibitor or a combination of inhibitors. An example of such an inhibitor is a compound of formula I, or a pharmaceutically acceptable salt thereof, wherein R1 to R7 are as described herein.Type: ApplicationFiled: July 10, 2023Publication date: November 2, 2023Applicant: The United States of America,as represented by the Secretary,Department of Health and Human ServicesInventors: Sanjay A. Desai, Ajay D. Pillai
-
Patent number: 11800983Abstract: Featured are methods, apparatus and devices for detecting a hematoma in tissue of a patient. In one aspect, such a method includes emitting near infrared light continuously into the tissue from a non-stationary near infrared light emitter and continuously monitoring the tissue using a non-stationary probe so as to continuously detect reflected light. The near infrared light is emitted at two distances from a brain of the patient, so the emitted light penetrates to two different depths. Such a method also includes applying a ratiometric analysis to the reflected light to distinguish a border between normal tissue and tissue exhibiting blood accumulation.Type: GrantFiled: August 30, 2017Date of Patent: October 31, 2023Assignees: The United States of America, as represented by the Secretary, Department of Health & Human Services, The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Jason D. Riley, Franck Amyot, Amir H. Gandjbakhche, James G. Smirniotopoulos, Eric Wassermann
-
Patent number: 11801153Abstract: Disclosed are powered gait assistance systems that include a controller, sensors, and a motor coupled to a patient's thigh and lower leg and operable to apply assistive torque to the patient's knee joint to assist the patient's volitional knee pivoting muscle output during selected stages of the patient's gait cycle, such that the assistive torque applied by the motor improves the patient's leg posture, muscle output, range of motion, and/or other parameters over the gait cycle. The sensors can include a torque sensor that measures torque applied by the motor, a knee angle sensor, a foot sensor that measures ground contact of the patient's foot, and/or other sensors. The controller can determine what stage of the patient's gait cycle the patient's leg is in based on sensor signals and cause the motor to apply corresponding assistive torque to the knee based on the gait cycle stage, sensor inputs, and known patient characteristics.Type: GrantFiled: July 31, 2017Date of Patent: October 31, 2023Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Thomas Bulea, Zachary Lerner, Diane Damiano, Andrew Gravunder
-
Publication number: 20230340066Abstract: Disclosed is a T cell receptor (TCR) having antigenic specificity for an HLA-A2-restricted epitope of human papillomavirus (HPV) 16 E6, E629-38. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells are also provided. Antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention are also provided. Also disclosed are methods of detecting the presence of a condition in a mammal and methods of treating or preventing a condition in a mammal, wherein the condition is cancer, HPV 16 infection, or HPV-positive premalignancy.Type: ApplicationFiled: May 25, 2023Publication date: October 26, 2023Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServicInventors: Christian S. Hinrichs, Steven A. Rosenberg
-
Patent number: 11793871Abstract: Vaccines that elicit broadly protective anti-influenza antibodies. The vaccines comprise nanoparticles that display HA trimers from Group 2 influenza virus on their surface. The nanoparticles are fusion proteins comprising a monomeric subunit (e.g., ferritin) joined to stabilized stem regions of Group 2 influenza virus HA proteins. The fusion proteins self-assemble to form the HA-displaying nanoparticles. Also provided are fusion proteins, and nucleic acid molecules encoding such proteins, and assays using nanoparticles of the invention to detect anti-influenza antibodies.Type: GrantFiled: May 11, 2022Date of Patent: October 24, 2023Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Jeffrey C. Boyington, Barney S. Graham, John R. Mascola, Hadi M. Yassine, Kizzmekia S. Corbett, Syed M. Moin, Lingshu Wang, Masaru Kanekiyo
-
Patent number: 11795177Abstract: The disclosure provides compounds of Formula I, which may be useful as aldehyde dehydrogenase inhibitors and the pharmaceutically acceptable salts thereof. The variables, J, R4, G, Q, and ring A are defined herein. Aldehyde dehydrogenase inhibitors of Formula I are useful for treating a variety of conditions including cancer and inflammation. The disclosure includes methods for using compounds and salts of Formula I to treat colon cancer, pancreatic cancer, nasopharyngeal carcinoma, thyroid cancer, prostate cancer, ovarian cancer, head and neck squamous cell carcinoma, lung cancer, hepatocellular carcinoma, leukemia, brain tumors breast cancer, atherosclerosis, ischaemic heart disease, acne vulgaris, asthma, autoimmune diseases, autoinflammatory diseases, chronic prostatitis, glomerulonephritis, inflammatory bowel disease, pelvic inflammatory disease, reperfusion injury, rheumatoid arthritis, sarcoidosis, transplant rejection, vasculitis, and interstitial cystitis.Type: GrantFiled: February 28, 2022Date of Patent: October 24, 2023Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human ServicesInventors: Shyh Ming Yang, David J. Maloney, Natalia Martinez, Adam Yasgar, Anton Simeonov
-
Patent number: 11795235Abstract: Disclosed is a molecule comprising: (a) a first domain, which comprises a targeting moiety; (b) a second domain, which comprises an albumin binding domain (ABD), (c) a third domain, which comprises a furin cleavage sequence (“FCS”), which FCS is cleavable by furin; and (d) a fourth domain, which comprises an optionally substituted Domain III from Pseudomonas exotoxin A (“PE”). Related nucleic acids, recombinant expression vectors, host cells, populations of cells, pharmaceutical compositions, methods of producing the molecule, methods of treating or preventing cancer in a mammal, and methods of inhibiting the growth of a target cell are also disclosed.Type: GrantFiled: September 18, 2018Date of Patent: October 24, 2023Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Ira H. Pastan, Junxia Wei, Masanori Onda, Tapan Bera, Mitchell Ho
-
Patent number: 11786589Abstract: A vaccine composition and method of vaccination are provided useful for immunizing a subject against a rotavirus. The vaccines include rotavirus strains CDC-9 and CDC-66, fragments thereof, homologues thereof, or combinations thereof. Inventive vaccines may include a fragment of CDC-9, CDC-66, homologues thereof, or combinations thereof. Methods of inducing an immunological response are provided by administering an inventive vaccine.Type: GrantFiled: June 16, 2021Date of Patent: October 17, 2023Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human ServicesInventors: Baoming Jiang, Roger I. Glass, Yuhuan Wang, Jon Gentsch
-
Patent number: 11787764Abstract: Heptamethine cyanines for use as fluorescent markers of the biliary and renal systems are disclosed. Certain heptamethine cyanines exhibit renal system specificity, while others exhibit biliary system specificity. The compounds may be used for diagnostic purposes and/or for visualization of renal or biliary systems during surgery.Type: GrantFiled: February 14, 2019Date of Patent: October 17, 2023Assignees: CHILDREN'S NATIONAL MEDICAL CENTER, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICESInventors: Martin John Schnermann, Peter C. W. Kim, Jaepyeong Cha, Roger Rauhauser Nani
-
Patent number: 11786591Abstract: Metapneumovirus (MPV) F proteins stabilized in a prefusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the MPV F proteins and/or nucleic acid molecules can be used to generate an immune response to MPV in a subject. In additional embodiments, the therapeutically effective amount of the MPV F ectodomain trimers and/or nucleic acid molecules can be administered to a subject in a method of treating or preventing MPV infection.Type: GrantFiled: May 28, 2021Date of Patent: October 17, 2023Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Institute for Research in BiomedicineInventors: Peter Kwong, Michael Gordon Joyce, Baoshan Zhang, Yongping Yang, Peter Collins, Ursula Buchholz, Davide Corti, Antonio Lanzavecchia, Guillaume Stewart-Jones
-
Publication number: 20230323425Abstract: Methods of sample preparation for detection of nucleic acids (such as viral nucleic acids, for example, viral RNA) are provided. In some examples, the methods include contacting a sample with a solution including a buffer containing about 0-0.5 mM EDTA and a chelating resin and incubating the resulting mixture at a temperature of at least about 55° C.Type: ApplicationFiled: August 12, 2021Publication date: October 12, 2023Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServicInventors: Bin Guan, Robert B. Hufnagel
-
Publication number: 20230321240Abstract: Disclosed are isolated or purified T cell receptors (TCRs) having antigenic specificity for human p53R273C or human p53Y220C. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.Type: ApplicationFiled: September 2, 2021Publication date: October 12, 2023Applicant: The United States of America,as represented by the Secretary,Department of Health and Human ServicesInventors: Sanghyun Kim, Nikolaos Zacharakis, Steven A. Rosenberg
-
Patent number: 11780931Abstract: Methods are provided for treating a subject with for an intracellular pathogen infection, by administering an agent that reduces the binding of CD47 on a infected cell to SIRP? on a host phagocytic cell, in an effective dose for increasing the phagocytosis of infected cells.Type: GrantFiled: December 14, 2021Date of Patent: October 10, 2023Assignees: The Board of Trustees of the Leland Stanford Junior University, The United States of America, as represented by the Secretary, Department of Health and Human Services, The Regents of the University of CaliforniaInventors: Kipp Andrew Weiskopf, Kim J. Hasenkrug, Cheryl A. Stoddart, Joseph McCrary McCune, Irving L. Weissman
-
Patent number: 11779570Abstract: The present invention concerns the use of compounds and compositions for the treatment or prevention of Flavivirus infections, such as dengue virus infections and Zika virus infections. Aspects of the invention include methods for treating or preventing Flavivirus virus infection, such as dengue virus and Zika virus infection, by administering a compound or composition of the invention, to a subject in need thereof; methods for inhibiting Flavivirus infections, such as dengue virus and Zika virus infections, in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits useful for treating or preventing Flavivirus infections, such as dengue virus and Zika virus infections.Type: GrantFiled: June 28, 2022Date of Patent: October 10, 2023Assignees: FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, Inc., The United States of America, as represented by the Secretary, Department of Health and Human Services, THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventors: Hengli Tang, Emily M. Lee, Wei Zheng, Ruili Huang, Miao Xu, Wenwei Huang, Khalida Shamim, Guoli Ming, Hongjun Song
-
Patent number: 11782065Abstract: Biomarkers tests which can be used to predict a positive or negative risk of preeclampsia are described. More specifically, a panel of biomarkers including MMP-7 and gpIIbIIIa, described. The test is useful to predict preeclampsia when a biological sample is obtained between the 16th and 22nd week of pregnancy. Prediction later in pregnancy can be achieved by a combination of Siglec-6, Activin A, ALCAM, and/or FCN2.Type: GrantFiled: December 21, 2021Date of Patent: October 10, 2023Assignees: Wayne State University, The United States of America, as Represented by the Secretary, Department of Health & Human ServicesInventors: Adi L. Tarca, Piya Chaemsaithong, Tinnakorn Chaiworapongsa, Sonia S. Hassan, Roberto Romero
-
Patent number: 11779603Abstract: Disclosed herein are T cell receptors (TCRs) capable of binding an antigen expressed by renal cell carcinoma cells. In some examples, the TCRs include an ? chain (such as SEQ ID NO: 2) and a ? chain (such as SEQ ID NO: 3). Also disclosed herein are vectors including nucleic acids encoding the disclosed TCR ? and/or ? chains. Further disclosed are modified T cells expressing the TCRs. In some examples, the modified T cells are prepared by transducing T cells with a vector including nucleic acids encoding the TCR ? chain and the TCR ? chain. In some embodiments, methods include treating a subject with RCC, by obtaining a population of T cells, transducing the population of T cells with a vector including a nucleic acids encoding the TCR ? chain and the TCR ? chain, and administering a composition comprising the modified T cells to the subject.Type: GrantFiled: June 30, 2017Date of Patent: October 10, 2023Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Loyola University of ChicagoInventors: Richard W. Childs, Michael I. Nishimura, Elena A. Cherkasova
-
Patent number: 11781955Abstract: This disclosure provides IR700-molecule conjugates and methods of their use to remove (e.g., separate or isolate) a target from a sample in vivo or from a subject in vitro. It is shown herein that exposure of IR700 to near infrared (NIR) light removes a portion of IR700, changing it from a hydrophilic molecule, to one that is hydrophobic, resulting in aggregation of IR700 and anything bound to it. For example, the disclosed IR700-molecule conjugates and methods provide photo-controlled ways to control the pharmacokinetics of a drug in vivo, and can be used to remove undesired agents from environmental or food samples or to isolate target molecules in a laboratory.Type: GrantFiled: September 21, 2020Date of Patent: October 10, 2023Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Hisataka Kobayashi, Peter Choyke, Martin John Schnermann